Literature DB >> 6733699

Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma.

L Hafström, A Hugander, P E Jönsson, H Westling, H Ehrsson.   

Abstract

In regional hyperthermic perfusion with melphalan for patients with malignant melanoma of the leg, plasma leakage between the perfusion circuit and the systemic circulation was 4-7 ml X min-1. The melphalan concentration in the perfusate was biphasic, with half-lives of 8-12 mins for the initial phase and 19-28 mins for the second phase, after the first dose. After a second dose, the corresponding values were 11-13 and 26-34 mins. The highest concentration in general circulation was 0.38 micrograms X ml-1.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6733699

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  6 in total

1.  Leakage measurement during selective limb perfusion using a gamma probe.

Authors:  D Sandrock; F Horst; W Gatzemeier; M Ghorbani; H Rauschecker; D L Munz; D Emrich
Journal:  Eur J Nucl Med       Date:  1996-05

2.  Continuous intraoperative external monitoring of perfusate leak using iodine-131 human serum albumin during isolated perfusion of the liver and limbs.

Authors:  W C Barker; M P Andrich; H R Alexander; D L Fraker
Journal:  Eur J Nucl Med       Date:  1995-11

3.  Rapid measurement of blood leakage during regional chemotherapy.

Authors:  C Alexander; G Omlor; R Berberich; G Gross; G Feifel
Journal:  Eur J Nucl Med       Date:  1993-03

4.  Leukocyte activation by isolated hyperthermic liver and limb perfusion due to malignancy.

Authors:  J P Arnestad; A Bengtsson; J P Bengtson; L Hafström; H Redl; G Schlag
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

5.  Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb.

Authors:  H F Rauschecker; H Foth; H C Michaelis; F Horst; W Gatzemeier; C Willenbrock; E Voth; G F Kahl
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.

Authors:  R N Scott; D J Kerr; R Blackie; J Hughes; G Burnside; R M MacKie; D S Byrne; A J McKay
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.